LumiraDx Reports Second Quarter 2022 Results
LumiraDx Limited (LMDX) announced its Q2 2022 financial results, reporting $44.7 million in revenue, a decline from $126.4 million in Q1 and $87.2 million in Q2 2021. The decrease is attributed to the transition of COVID-19 from a pandemic to an endemic phase. The company has achieved five new CE Marks for various tests and is advancing its product pipeline, including a U.S. submission for a SARS-CoV-2 test. Total operating loss reached $81 million, with a cash balance of $106 million. A recent public offering raised $100 million, enhancing liquidity.
- Achieved five new CE Marks for tests, enhancing product portfolio.
- Completed a public offering raising approximately $100 million, improving liquidity.
- Continued advancement of the molecular pipeline with promising programs.
- Q2 2022 revenue decreased by 65% compared to Q1 2022 ($126.4 million) and by 48% compared to Q2 2021 ($87.2 million).
- Operating loss increased to $81 million, up from $42 million in the same quarter last year.
- Gross margins declined to 11%, down from 17% year-over-year, due to under-absorbed manufacturing capacity.
Strong Pipeline Progress and Commercialization Priorities for Newly Authorized Products
LONDON, Aug. 18, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced operational and financial results for the second quarter ended June 30, 2022.
- Q2 2022 revenue of
$44.7 million compared to Q1 2022 revenue of$126.4 million and Q2 2021 revenue of$87.2 million as COVID-19 moves from pandemic to endemic stage - Five new CE Marks including HbA1c, NT-ProBNP, SARS-CoV-2 Ag Ultra and Ultra Pool tests with results in five minutes, as well as SARS-CoV-2 & RSV combo; expanded use of CRP to pediatric populations and a new exclusion claim for D-Dimer
- Actively working on U.S. 510K submission for the SARS-CoV-2 Ag Ultra 5-minute test, with clinical trials planned for broader respiratory portfolio during flu season this year
- Molecular pipeline continues to progress well with Strep A and TB programs validating the performance and speed that can be achieved with proprietary qSTAR technology
- As previously announced, completed financings during the third quarter of 2022 for aggregate net proceeds of approximately
$100 million , including an additional investment from the Bill & Melinda Gates Foundation, and initiated a restructuring program to shape organization and cost structure for successful innovation and commercialization in line with our mission to transform community-based healthcare
“We have made significant progress on expanding our portfolio of newly authorized products and have exciting commercialization priorities,” said LumiraDx Chairman and CEO Ron Zwanziger. “We are moving to commercialize our product portfolio in Europe and other international markets while actively working on U.S. submissions and preparing clinical trials this fall. We believe that we have a compelling value proposition with products designed to disrupt the point of care market and enable customers to consolidate three to six different instruments they are currently using into a single LumiraDx Platform. With lab comparable results in minutes for diabetes, heart failure, and coagulation disorders, we see an opportunity to do more testing in emergency rooms and primary care offices. We’re also accelerating the development of our Troponin and molecular assays on the Platform. We are confident these actions and strategic priorities for the next 12 to 18 months will bridge us toward key revenue milestones and support our strategy to transform community-based care.”
2022 Second Quarter Financial Highlights
For the three months ended June 30, 2022, LumiraDx delivered revenue of
Revenues declined from the early months of this year at the height of the Omicron surge as COVID-19 moves from pandemic to endemic stage. At the same time, LumiraDx’s products continue to be recognized by customers for their significant performance and cost advantages over competing products. In response to lower COVID testing activity and to ensure efficient use of cash, the company initiated a global restructuring plan to resize the organization to the current requirements to meet market needs and to reduce costs. The company is targeting cost reductions to avoid impacts on pipeline delivery on its test menu for common health conditions to drive near-term revenue growth.
Total gross margins for the second quarter of 2022 were
Research and development expenses were
The company announced a restructuring program to reduce overall operating costs and deprioritizing certain R&D activities for earlier stage programs.
Second quarter 2022 sales, marketing and administrative expenses were
Operating loss for the second quarter of 2022 was
Our cash balance at the end of the second quarter was
Conference Call
LumiraDx’s senior management team will host a conference call today at 8:00 AM ET to discuss the company’s financial results and business updates. Call in details and a link to view the webcast may be found at investors.lumiradx.com/news-and-events/investor-calendar. A replay of the webcast will be available on the Investor's section of the company's website at investors.lumiradx.com shortly after the conclusion of the call. The webcast will be archived for one year.
About LumiraDx
LumiraDx Limited (Nasdaq: LMDX) is next-generation point of care diagnostics company that is transforming community-based healthcare. Its actively controlled microfluidic technology provides fast, high performance and accessible diagnostic solutions wherever the patient is for nearly any testing scenario, creating unique testing options at the point of need.
The company offers a broad menu of lab comparable tests on a single portable Platform, with more than 30 assays on the market or in development, covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. The company also supports high-complexity laboratory testing in an accessible high-throughput format to leverage current molecular laboratory operations.
Founded in 2014 and based in the UK, LumiraDx's diagnostic testing solutions are being deployed globally by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness as well as disease.
More information on LumiraDx is available at www.lumiradx.com.
Contact:
Colleen McMillen
Colleen.McMillen@lumiradx.com
+1.917.344.9360
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the effectiveness of our strategy, regulatory progress and the advancement of our pipeline of tests, the timing and results of our clinical trials, the benefits and performance of our tests, our ability to reach key revenue milestones and the expected timing and outcome of our restructuring activities. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, including, among others, general economic, political and business conditions; the effect of COVID-19 on LumiraDx's business and financial results; obtaining or maintaining regulatory approval, authorization or clearance for our tests; and those factors discussed under the header "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2021,which was filed with the Securities and Exchange Commission, or SEC on April 13, 2022, in our report on Form 6-K that was filed with the SEC on August 16, 2022, and in other filings that we make with the SEC. Although LumiraDx believes that it has a reasonable basis for each forward-looking statement contained in this press release, LumiraDx cautions you that these statements are based on a combination of facts and factors currently known by it and its projections of the future, about which it cannot be certain. LumiraDx undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Non-IFRS Financial Measures
We present non-IFRS financial measures because we believe that they and other similar measures are widely used by certain investors, securities analysts and other interested parties as supplemental measures of performance and liquidity. We also use these measures internally to establish forecasts, budgets and operational goals to manage and monitor our business, as well as evaluate our underlying historical performance, as we believe that these non-IFRS financial measures depict the true performance of the business by encompassing only relevant and controllable events, enabling us to evaluate and plan more effectively for the future. The non-IFRS financial measures may not be comparable to other similarly titled measures of other companies and have limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of our operating results as reported under IFRS as issued by the IASB. Non-IFRS financial measures and margins are not measurements of our performance, financial condition or liquidity under IFRS as issued by the IASB and should not be considered as alternatives to operating loss, gross margin or net income (loss) or any other performance measures, derived in accordance with IFRS as issued by the IASB or any other generally accepted accounting principles.
We define non-IFRS operating loss and non-IFRS net income (loss) as operating loss and net income (loss), respectively, excluding amortization, share-based payments, IFRS 2 listing expense, change in fair value of financial instruments, foreign exchange (gain)/loss, dividends on preferred shares and non-cash interest. We define non-IFRS expenses as expenses excluding amortization and share-based payments. We recommend that you review the reconciliation of the non-IFRS measure to the most directly comparable IFRS financial measure provided in the financial statement tables included below, and that you not rely on any single financial measure to evaluate our business.
| LUMIRADX LIMITED | |||||||
| Unaudited Consolidated Statement of Financial Position | |||||||
| JUNE 30, 2022 | DECEMBER 31, 2021 | ||||||
| (in thousands, except share data) | |||||||
| ASSETS | |||||||
| Non–Current Assets | |||||||
| Other non-current assets | $ | 510 | $ | 569 | |||
| Intangibles and goodwill | 33,088 | 37,048 | |||||
| Right-of-Use Assets | 24,103 | 27,746 | |||||
| Property, plant and equipment | 160,974 | 173,397 | |||||
| Total Non-Current Assets | 218,675 | 238,760 | |||||
| Current Assets | |||||||
| Inventories | 169,557 | 149,055 | |||||
| Tax receivable | 15,540 | 15,022 | |||||
| Trade and other receivables | 64,117 | 109,798 | |||||
| Cash and cash equivalents | 106,450 | 132,145 | |||||
| Total Current Assets | 355,664 | 406,020 | |||||
| TOTAL ASSETS | $ | 574,339 | $ | 644,780 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Non-Current Liabilities | |||||||
| Debt due after more than one year | $ | (358,747 | ) | $ | (301,129 | ) | |
| Other Long Term Liabilities | (43,112 | ) | - | ||||
| Lease liabilities | (22,230 | ) | (25,514 | ) | |||
| Stock Warrants | (5,462 | ) | (10,407 | ) | |||
| Deferred tax liabilities | (537 | ) | (779 | ) | |||
| Total Non-Current Liabilities | (430,088 | ) | (337,829 | ) | |||
| Current Liabilities | |||||||
| Debt due within one year | (118 | ) | (191 | ) | |||
| Government and other grants | (32,216 | ) | (38,941 | ) | |||
| Trade and other payables | (89,927 | ) | (99,641 | ) | |||
| Lease liabilities due within one year | (6,495 | ) | (5,582 | ) | |||
| Total Current Liabilities | (128,756 | ) | (144,355 | ) | |||
| Equity | |||||||
| Share capital and share premium | (758,114 | ) | (754,023 | ) | |||
| Foreign currency translation reserve | (15,253 | ) | 19,706 | ||||
| Other reserves | (104,957 | ) | (104,957 | ) | |||
| Accumulated deficit | 862,513 | 676,223 | |||||
| Total equity attributable to equity holders of the parent | (15,811 | ) | (163,051 | ) | |||
| Non-controlling interests | 316 | 455 | |||||
| Total Equity | (15,495 | ) | (162,596 | ) | |||
| TOTAL EQUITY AND LIABILITIES | $ | (574,339 | ) | $ | (644,780 | ) | |
| LUMIRADX LIMITED | ||||||||||||||||
| Unaudited Consolidated Statement of Profit and Loss and Comprehensive Income | ||||||||||||||||
| THREE MONTHS ENDED JUNE 30, | SIX MONTHS ENDED JUNE 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||
| Revenue | $ | 44,726 | $ | 87,222 | $ | 171,138 | $ | 194,094 | ||||||||
| Cost of sales | (39,889 | ) | (72,359 | ) | (116,275 | ) | (135,914 | ) | ||||||||
| Gross Profit | 4,837 | 14,863 | 54,863 | 58,180 | ||||||||||||
| Research and development expenses | (47,450 | ) | (34,262 | ) | (88,769 | ) | (61,003 | ) | ||||||||
| Selling, marketing and administrative expenses | (37,845 | ) | (26,947 | ) | (78,001 | ) | (64,998 | ) | ||||||||
| Operating Loss | (80,458 | ) | (46,346 | ) | (111,907 | ) | (67,821 | ) | ||||||||
| Finance income | 188 | 71,024 | 5,139 | 5,041 | ||||||||||||
| Finance expense | (67,858 | ) | (38,205 | ) | (95,315 | ) | (131,623 | ) | ||||||||
| Net finance expense | (67,670 | ) | 32,819 | (90,176 | ) | (126,582 | ) | |||||||||
| Gain/(Loss) before Tax | (148,128 | ) | (13,527 | ) | (202,083 | ) | (194,403 | ) | ||||||||
| Tax (provision)/credit for the period | 732 | (1,644 | ) | (1,485 | ) | (1,557 | ) | |||||||||
| Gain/(Loss) for the period | $ | (147,396 | ) | $ | (15,171 | ) | $ | (203,568 | ) | $ | (195,960 | ) | ||||
| Loss attributable to non-controlling interest | 61 | 278 | 139 | 322 | ||||||||||||
| Net gain/(loss) attributable to equity holders of parent—basic and diluted | $ | (147,457 | ) | $ | (15,449 | ) | $ | (203,707 | ) | $ | (196,282 | ) | ||||
| Net gain/(loss) per share attributable to equity holders of parent—basic | $ | (0.58 | ) | $ | (0.12 | ) | $ | (0.80 | ) | $ | (1.48 | ) | ||||
| Net gain/(loss) per share attributable to equity holders of parent—diluted | $ | (0.58 | ) | $ | (0.12 | ) | $ | (0.80 | ) | $ | (1.48 | ) | ||||
| Weighted-average number of Ordinary Shares used in loss per share—basic | 254,686,967 | 132,204,201 | 253,945,274 | 132,204,201 | ||||||||||||
| Weighted-average number of Ordinary Shares used in loss per share—diluted | 254,686,967 | 132,204,201 | 253,945,274 | 132,204,201 | ||||||||||||
| LUMIRADX LIMITED | ||||||||||||||||||||||||||||||||
| Unaudited Reconciliation of IFRS Financial Measures to Non-IFRS Financial Measures | ||||||||||||||||||||||||||||||||
| THREE MONTHS ENDED JUNE 30, | ||||||||||||||||||||||||||||||||
| Cost of Goods Sold | Research and Development | Selling, Marketing and Administrative | ||||||||||||||||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||||||||
| (in thousands) | ||||||||||||||||||||||||||||||||
| IFRS Financial Measure | $ | (39,889 | ) | $ | (72,359 | ) | $ | (47,450 | ) | $ | (34,262 | ) | $ | (37,845 | ) | $ | (26,947 | ) | ||||||||||||||
| Amortization | - | - | 39 | 44 | 459 | 542 | ||||||||||||||||||||||||||
| Share-based payments | 621 | - | 2,266 | 323 | 6,554 | 3,956 | ||||||||||||||||||||||||||
| Non-IFRS Adjusted Financial Measure | $ | (39,268 | ) | $ | (72,359 | ) | $ | (45,145 | ) | $ | (33,895 | ) | $ | (30,832 | ) | $ | (22,449 | ) | ||||||||||||||
| THREE MONTHS ENDED JUNE 30, | ||||||||||||||||||||||||||||||||
| Gross Margin | Operating Loss | Net Loss | Diluted EPS | |||||||||||||||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||||||
| (in thousands, except per share data) | ||||||||||||||||||||||||||||||||
| IFRS Financial Measure | $ | 4,837 | $ | 14,863 | $ | (80,458 | ) | $ | (46,346 | ) | $ | (147,396 | ) | $ | (15,171 | ) | $ | (0.58 | ) | $ | (0.12 | ) | ||||||||||
| Amortization | - | - | 498 | 586 | 498 | 586 | - | 0.01 | ||||||||||||||||||||||||
| Share-based payments | 621 | - | 9,441 | 4,279 | 9,441 | 4,279 | 0.04 | 0.03 | ||||||||||||||||||||||||
| Change in fair value of financial instruments | - | - | - | - | 471 | (70,850 | ) | - | (0.54 | ) | ||||||||||||||||||||||
| Foreign exchange loss/(gain) | - | - | - | - | 55,512 | 1,716 | 0.22 | 0.02 | ||||||||||||||||||||||||
| Accretion of royalty financing | - | - | - | - | 1,612 | - | 0.01 | - | ||||||||||||||||||||||||
| Dividends on preferred shares | - | - | - | - | - | 5,384 | - | 0.04 | ||||||||||||||||||||||||
| Non-cash interest | - | - | - | - | 1,890 | 21,385 | - | 0.16 | ||||||||||||||||||||||||
| Non-IFRS Adjusted Financial Measure | $ | 5,458 | $ | 14,863 | $ | (70,519 | ) | $ | (41,481 | ) | $ | (77,972 | ) | $ | (52,671 | ) | $ | (0.31 | ) | $ | (0.40 | ) | ||||||||||
| Adjusted Gross Profit Margin | 12 | % | 17 | % | ||||||||||||||||||||||||||||
| SIX MONTHS ENDED JUNE 30, | ||||||||||||||||||||||||||||||||
| Cost of Goods Sold | Research and Development | Selling, Marketing and Administrative | ||||||||||||||||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||||||||
| (in thousands) | ||||||||||||||||||||||||||||||||
| IFRS Financial Measure | $ | (116,275 | ) | $ | (135,914 | ) | $ | (88,769 | ) | $ | (61,003 | ) | $ | (78,001 | ) | $ | (64,998 | ) | ||||||||||||||
| Amortization | - | - | 81 | 88 | 942 | 1,080 | ||||||||||||||||||||||||||
| Share-based payments | 1,024 | - | 3,780 | 1,047 | 12,613 | 24,234 | ||||||||||||||||||||||||||
| Non-IFRS Adjusted Financial Measure | $ | (115,251 | ) | $ | (135,914 | ) | $ | (84,908 | ) | $ | (59,868 | ) | $ | (64,446 | ) | $ | (39,684 | ) | ||||||||||||||
| SIX MONTHS ENDED JUNE 30, | ||||||||||||||||||||||||||||||||
| Gross Margin | Operating Loss | Net Loss | Diluted EPS | |||||||||||||||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||||||
| (in thousands, except per share data) | ||||||||||||||||||||||||||||||||
| IFRS Financial Measure | $ | 54,863 | $ | 58,180 | $ | (111,907 | ) | $ | (67,821 | ) | $ | (203,568 | ) | $ | (195,960 | ) | $ | (0.80 | ) | $ | (1.48 | ) | ||||||||||
| Amortization | - | - | 1,023 | 1,168 | 1,023 | 1,168 | - | 0.01 | ||||||||||||||||||||||||
| Share-based payments | - | 17,417 | 25,281 | 17,417 | 25,281 | 0.07 | 0.19 | |||||||||||||||||||||||||
| Change in fair value of financial instruments | - | - | - | - | (4,945 | ) | 60,252 | (0.02 | ) | 0.46 | ||||||||||||||||||||||
| Foreign exchange loss/(gain) | - | - | - | - | 74,721 | (4,828 | ) | 0.30 | (0.04 | ) | ||||||||||||||||||||||
| Accretion of royalty financing | - | - | - | - | 1,612 | - | 0.01 | - | ||||||||||||||||||||||||
| Dividends on preferred shares | - | - | - | - | - | 10,711 | - | 0.08 | ||||||||||||||||||||||||
| Non-cash interest | - | - | - | - | 3,669 | 42,652 | 0.01 | 0.32 | ||||||||||||||||||||||||
| Non-IFRS Adjusted Financial Measure | $ | 54,863 | $ | 58,180 | $ | (93,467 | ) | $ | (41,372 | ) | $ | (110,071 | ) | $ | (60,724 | ) | $ | (0.43 | ) | $ | (0.46 | ) | ||||||||||
| Adjusted Gross Profit Margin | 32 | % | 30 | % | ||||||||||||||||||||||||||||
| LUMIRADX LIMITED | ||||||||||||||||
| Unaudited Consolidated Statement of Cash Flows | ||||||||||||||||
| THREE MONTHS ENDED | SIX MONTHS ENDED | |||||||||||||||
| JUNE 30, | JUNE 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||
| Cash Flows from Operating Activities | ||||||||||||||||
| Income/(Loss) for the period | $ | (147,396 | ) | $ | (15,171 | ) | $ | (203,568 | ) | $ | (195,960 | ) | ||||
| Adjustments to reconcile loss for the period to net cash used in operating activities: | ||||||||||||||||
| Depreciation | 7,501 | 4,049 | 15,381 | 7,539 | ||||||||||||
| Amortization | 498 | 586 | 1,023 | 1,168 | ||||||||||||
| Net finance (income)/expenses | 67,102 | (37,803 | ) | 89,637 | 116,059 | |||||||||||
| Equity based share based payment transactions | 9,441 | 4,279 | 17,417 | 25,281 | ||||||||||||
| Increase in tax receivable | (565 | ) | (685 | ) | (2,035 | ) | (1,373 | ) | ||||||||
| Accrued preferred shares dividends | - | 5,384 | - | 10,711 | ||||||||||||
| Changes to working capital: | ||||||||||||||||
| Inventories | (13,684 | ) | (31,148 | ) | (32,292 | ) | (88,807 | ) | ||||||||
| Trade and other receivables | 11,331 | 5,128 | 43,171 | 53,619 | ||||||||||||
| Trade payables and other liabilities | (17,015 | ) | 16,752 | (13,217 | ) | 13,863 | ||||||||||
| Net Cash used in Operating Activities | (82,787 | ) | (48,629 | ) | (84,483 | ) | (57,900 | ) | ||||||||
| Cash Flows from Investing Activities | ||||||||||||||||
| Purchases of property, plant, equipment | (6,465 | ) | (26,314 | ) | (16,727 | ) | (61,741 | ) | ||||||||
| Cash paid for business acquisitions, net of cash received | - | (1,968 | ) | - | (1,968 | ) | ||||||||||
| Cash received from merger | - | - | - | - | ||||||||||||
| Net Cash generated from/(used in) Investing Activities | (6,465 | ) | (28,282 | ) | (16,727 | ) | (63,709 | ) | ||||||||
| Cash Flows from Financing Activities | ||||||||||||||||
| Proceeds from issuance of convertible notes, net of issuance costs | (316 | ) | - | 54,009 | - | |||||||||||
| Proceeds from royalty agreement | 41,500 | - | 41,500 | - | ||||||||||||
| Proceeds from debt issuance, net of issuance costs | - | (2,581 | ) | - | 361,729 | |||||||||||
| Proceeds from shares issued on the exercise of share options | 3,017 | - | 4,091 | - | ||||||||||||
| Repayment of principal portion of lease liabilities | (1,407 | ) | (1,086 | ) | (2,946 | ) | (2,258 | ) | ||||||||
| Cash interest paid, net of interest received | (6,151 | ) | (9,105 | ) | (12,251 | ) | (14,627 | ) | ||||||||
| Fee on early extinguishment of debt | - | - | - | (2,350 | ) | |||||||||||
| Repayments of debt | (35 | ) | (117 | ) | (118 | ) | (140,220 | ) | ||||||||
| Net Cash (used in)/generated from Financing Activities | 36,608 | (12,889 | ) | 84,285 | 202,274 | |||||||||||
| Net (Decrease)/Increase in Cash and Cash Equivalents | $ | (52,644 | ) | $ | (89,800 | ) | $ | (16,925 | ) | $ | 80,665 | |||||
| Movement in Cash and Cash Equivalents | ||||||||||||||||
| Cash and cash equivalents at the beginning of the period | 166,046 | 334,518 | 132,145 | 161,172 | ||||||||||||
| Exchange gain/(loss) on cash and cash equivalents | (6,952 | ) | 1,737 | (8,770 | ) | 4,618 | ||||||||||
| Net increase/(decrease) in cash and cash equivalents | (52,644 | ) | (89,800 | ) | (16,925 | ) | 80,665 | |||||||||
| Cash and Cash Equivalents at the end of the period | $ | 106,450 | $ | 246,455 | $ | 106,450 | $ | 246,455 | ||||||||
FAQ
What were LumiraDx's Q2 2022 revenue figures?
How much operating loss did LumiraDx incur in Q2 2022?
What new products did LumiraDx achieve CE Marks for?
What was LumiraDx's cash balance at the end of Q2 2022?
How did LumiraDx's gross margins change in Q2 2022?
What major financing event occurred for LumiraDx in Q3 2022?
